MicroRNA‑431 serves as a tumor inhibitor in breast cancer through targeting FGF9

Wang,Wei; Dong,Yan; Li,Xiaoyan; Pan,Yingying; Du,Jiexin; Liu,Daotong

doi:10.3892/ol.2019.11126

MicroRNA‑431 serves as a tumor inhibitor in breast cancer through targeting FGF9

Authors:
- Wei Wang
- Yan Dong
- Xiaoyan Li
- Yingying Pan
- Jiexin Du
- Daotong Liu
View Affiliations

Affiliations: Department of General Surgery, Zhangqiu Maternity and Child Care Hospital, Jinan, Shandong 250200, P.R. China, Breast Clinic Center, Qingdao Central Hospital, Qingdao, Shandong 266042, P.R. China, Department of Clinical Nutrition, The People's Hospital of Zhangqiu Area, Jinan, Shandong 250200, P.R. China, Renal Rheumatism Intervention Department, The People's Hospital of Zhangqiu Area, Jinan, Shandong 250200, P.R. China, Department of Neurology, The People's Hospital of Zhangqiu Area, Jinan, Shandong 250200, P.R. China, Department of Breast and Thyroid Surgery, Jining No. 1 People's Hospital, Jining, Shandong 272000, P.R. China
Published online on: November 20, 2019 https://doi.org/10.3892/ol.2019.11126
Pages: 1001-1007
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer has become an important public health problem. Moreover, the functions of microRNA‑431 (miR‑431) have been detected in human cancers other than breast cancer. Hence, we investigated the role of miR‑431 in progression of breast cancer. RT‑qPCR and Western blot analysis were performed to assess expression of miR‑431 and genes. The regulatory mechanism of miR‑431 was investigated using MTT, Transwell and luciferase reporter assay. Decreased miR‑431 expression was identified in breast cancer, which was related to aggressive behavior. Furthermore, miR‑431 restrained cell proliferation, metastasis and EMT in breast cancer. miR‑431 induced apoptosis through enhancing Bax expression. In addition, miR‑431 was found to directly target FGF9. Moreover, upregulation of FGF9 impaired the anti‑tumor effect of miR‑431 in breast cancer. miR‑431 restrained cell viability and metastasis in breast cancer through targeting FGF9, indicating that miR‑431 serves as a tumor inhibitor in breast cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI
3	Strom C: Breast cancer: Diagnostic service shares BRCA data. Nature. 522:342015. View Article : Google Scholar : PubMed/NCBI
4	Zhou M, Zhong L, Xu W, Sun Y, Zhang Z, Zhao H, Yang L and Sun J: Discovery of potential prognostic long non-coding RNA biomarkers for predicting the risk of tumor recurrence of breast cancer patients. Sci Rep. 6:310382016. View Article : Google Scholar : PubMed/NCBI
5	Yin Y, Cai J, Meng F, Sui C and Jiang Y: miR-144 suppresses proliferation, invasion, and migration of breast cancer cells through inhibiting CEP55. Cancer Biol Ther. 19:306–315. 2018. View Article : Google Scholar : PubMed/NCBI
6	Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB and Dornan D: miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. PLoS One. 8:e665022013. View Article : Google Scholar : PubMed/NCBI
7	Yang X and Meng T: MicroRNA-431 affects trophoblast migration and invasion by targeting ZEB1 in preeclampsia. Gene. 683:225–232. 2019. View Article : Google Scholar : PubMed/NCBI
8	Kwok GTY, Zhao JT, Glover AR, Gill AJ, Clifton-Bligh R, Robinson BG, Ip JCY and Sidhu SB: microRNA-431 as a chemosensitizer and potentiator of drug activity in adrenocortical carcinoma. Oncologist. 24:e241–e250. 2019. View Article : Google Scholar : PubMed/NCBI
9	Lee KP, Shin YJ, Panda AC, Abdelmohsen K, Kim JY, Lee SM, Bahn YJ, Choi JY, Kwon ES, Baek SJ, et al: miR-431 promotes differentiation and regeneration of old skeletal muscle by targeting Smad4. Genes Dev. 29:1605–1617. 2015. View Article : Google Scholar : PubMed/NCBI
10	Liu Y, Li L, Liu Z, Yuan Q and Lu X: Downregulation of miR-431 expression associated with lymph node metastasis and promotes cell invasion in papillary thyroid carcinoma. Cancer Biomark. 22:727–732. 2018. View Article : Google Scholar : PubMed/NCBI
11	Yang J, Zhu H, Jin Y and Song Y: miR-431 inhibits cell proliferation and induces cell apoptosis by targeting CDK14 in pancreatic cancer. Eur Rev Med Pharmacol Sci. 22:4493–4499. 2018.PubMed/NCBI
12	Su N, Jin M and Chen L: Role of FGF/FGFR signaling in skeletal development and homeostasis: Learning from mouse models. Bone Res. 2:140032014. View Article : Google Scholar : PubMed/NCBI
13	Ohgino K, Soejima K, Yasuda H, Hayashi Y, Hamamoto J, Naoki K, Arai D, Ishioka K, Sato T, Terai H, et al: Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer. Lung Cancer. 83:90–96. 2014. View Article : Google Scholar : PubMed/NCBI
14	Wang S, Lin H, Zhao T, Huang S, Fernig DG, Xu N, Wu F, Zhou M, Jiang C and Tian H: Expression and purification of an FGF9 fusion protein in E. coli, and the effects of the FGF9 subfamily on human hepatocellular carcinoma cell proliferation and migration. Appl Microbiol Biotechnol. 101:7823–7835. 2017. View Article : Google Scholar : PubMed/NCBI
15	Li K, Pan J, Wang J, Liu F and Wang L: miR-665 regulates VSMCs proliferation via targeting FGF9 and MEF2D and modulating activities of Wnt/β-catenin signaling. Am J Transl Res. 9:4402–4414. 2017.PubMed/NCBI
16	Yang H, Fang F, Chang R and Yang L: MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology. 58:205–217. 2013. View Article : Google Scholar : PubMed/NCBI
17	Li W, Yi J, Zheng X, Liu S, Fu W, Ren L, Li L, Hoon DSB, Wang J and Du G: miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway. Clin Epigenetics. 10:642018. View Article : Google Scholar : PubMed/NCBI
18	Zhang J, He Y, Yu Y, Chen X, Cui G, Wang W, Zhang X, Luo Y, Li J, Ren F, et al: Upregulation of miR-374a promotes tumor metastasis and progression by downregulating LACTB and predicts unfavorable prognosis in breast cancer. Cancer Med. 7:3351–3362. 2018. View Article : Google Scholar
19	Jiang Q, Cheng L, Ma D and Zhao Y: FBXL19-AS1 exerts oncogenic function by sponging miR-431-5p to regulate RAF1 expression in lung cancer. Biosci Rep. 39:392019. View Article : Google Scholar
20	Li MF, Li YH, He YH, Wang Q, Zhang Y, Li XF, Meng XM, Huang C and Li J: Emerging roles of hsa_circ_0005075 targeting miR-431 in the progress of HCC. Biomed Pharmacother. 99:848–858. 2018. View Article : Google Scholar : PubMed/NCBI
21	Pan L, Ren F, Rong M, Dang Y, Luo Y, Luo D and Chen G: Correlation between down-expression of miR-431 and clinicopathological significance in HCC tissues. Clin Transl Oncol. 17:557–563. 2015. View Article : Google Scholar : PubMed/NCBI
22	Sun K, Zeng T, Huang D, Liu Z, Huang S, Liu J and Qu Z: MicroRNA-431 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the ZEB1-mediated epithelial-mensenchymal transition. FEBS Open Bio. 5:900–907. 2015. View Article : Google Scholar : PubMed/NCBI
23	Xu CM, Chen LX, Gao F, Zhu MF, Dai Y, Xu Y and Qian WX: miR-431 suppresses proliferation and metastasis of lung cancer via down-regulating DDX5. Eur Rev Med Pharmacol Sci. 23:699–707. 2019.PubMed/NCBI
24	Wu YZ, Chan KYY, Leung KT, Lam HS, Tam YH, Lee KH, Li K and Ng PC: Dysregulation of miR-431 and target gene FOXA1 in intestinal tissues of infants with necrotizing enterocolitis. FASEB J. 33:5143–5152. 2019. View Article : Google Scholar : PubMed/NCBI
25	Kong Q, Han J, Deng H, Wu F, Guo S and Ye Z: miR-431-5p alters the epithelial-to-mesenchymal transition markers by targeting UROC28 in hepatoma cells. OncoTargets Ther. 11:6489–6503. 2018. View Article : Google Scholar
26	Yu B, Qian T, Wang Y, Zhou S, Ding G, Ding F and Gu X: miR-182 inhibits Schwann cell proliferation and migration by targeting FGF9 and NTM, respectively at an early stage following sciatic nerve injury. Nucleic Acids Res. 40:10356–10365. 2012. View Article : Google Scholar : PubMed/NCBI
27	Rao C, Miao X, Zhao G, Zhang C, Shen H, Dong C and Yang M: miR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9. Biomed Pharmacother. 114:1086622019. View Article : Google Scholar : PubMed/NCBI
28	Deng M, Tang HL, Lu XH, Liu MY, Lu XM, Gu YX, Liu JF and He ZM: miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer. PLoS One. 8:e726622013. View Article : Google Scholar : PubMed/NCBI
29	Liang H, Luo R, Chen X, Zhao Y and Tan A: miR-187 inhibits the growth of cervical cancer cells by targeting FGF9. Oncol Rep. 38:1977–1984. 2017. View Article : Google Scholar : PubMed/NCBI
30	Wang R, Sun Y, Yu W, Yan Y, Qiao M, Jiang R, Guan W and Wang L: Downregulation of miRNA-214 in cancer-associated fibroblasts contributes to migration and invasion of gastric cancer cells through targeting FGF9 and inducing EMT. J Exp Clin Cancer Res. 38:202019. View Article : Google Scholar : PubMed/NCBI